Anticanine FVIII inhibitory antibody development in treated dogs.

Plasma was collected from the dogs at the indicated times prior to and following vector treatment and tested for the presence of FVIII inhibitory antibodies by Bethesda assay. (A) Bethesda titer of dog A. (B) Bethesda titer of dog B. (C) Bethesda titer of dogs C and D. All animals displayed a Bethesda titer of 0 prior to vector treatment. Final titer for dog A was 46.0 BU at 22 months; final titer for dog B was 2.3 BU at 22 months; final titer for dog C was 0 BU at 16 months; and final titer for dog D was 0 BU at 16 months.